Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Darbepoetin Alfa Risks Outweigh Benefits for Patients With CKD, Diabetes, and Anaemia: Presented at Renal Week 2009 - (DGDispatch)
    Fenofibrate May Protect Diabetics Against Loss of Renal Function: Presented at Renal Week 2009 - (DGDispatch)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    TopAbstracts in Diabetes 11/03/2009 - (DGNews)
    Paricalcitol Added to Hypertension Therapy Lowers Albuminuria in Patients With Diabetes and Chronic Kidney Disease: Presented at Renal Week 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Diabetes
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Cases in Practice: Incretin-Based Therapies for Common Patient Encounters
      Diabetes Management - Pearls of Lipid Control
      Obesity Management in Patients with Type 2 Diabetes

      Webcasts/CME archive

       Recent cases - Diabetes
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Compound Heterozygous Mutation of Aquaporin 2 Gene in Woman Patient with Congenital Nephrogenic Diabetes Insipidus

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Painful Diabetic Neuropathy Often Inadequately Treated: Presented at ADA

        By Jill Stein


        ORLANDO, FL -- June 7, 2004 -- Improved management of painful diabetic neuropathy is desperately needed, according to researchers.

        On June 5th, at the 64th Scientific Sessions of the American Diabetes Association (ADA), Nancy Brandenburg, PhD, with Pfizer, Inc. in New York, presented the results of a community-based cross sectional study undertaken to assess pain severity, medication use and perceived treatment satisfaction among patients with painful diabetic neuropathy (DPN). Patients in the study had been treated by endocrinologists, neurologists, anesthesiologists, and primary care physicians.

        Distal symmetric sensorimotor polyneuropathy is the most common diabetic peripheral neuropathy and affects between 16.3% and 50% of patients with diabetes.

        Questionnaires were completed by 255 patients with a known history of DPN between April and October 2003. "Our results showed that pain levels remained high and satisfaction with pain management remained low despite extensive treatment," said Dr. Brandenburg.

        The mean age of the study population was 61 years, the mean duration of diabetes was 12 years, and the mean duration of diabetic neuropathy was 6.4 years.

        The study revealed that a majority (90.6%) of patients had painful diabetic peripheral neuropathy for at least 1 year prior to the survey. About three-quarters of the patients reported moderate-to-severe average and worst pain severity.

        In addition, 75.3% of patients had used prescription medications for painful diabetic peripheral neuropathy for at least 1 year prior to the survey.

        Most of the patients had used a range of prescription medications for the relief of painful diabetic neuropathy in the week before they completed the questionnaire - 79.2% had used at least one drug while 52.1% had taken at least 2. Overall, 46.7% of patients reported using non-steroidal anti-inflammatory drugs (NSAIDs). "This is disappointing given that this class of drugs has not been approved for this indication," Dr. Brandenburg said.

        Few patients reported using amitriptyline and gabapentin, both of which have been recommended as first-line treatments for neuropathic pain.

        Overall, 41.9% of patients recruited through primary care physician reported using polytherapy from more than 1 of the following therapeutic classes: opioids, NSAIDs, antiepileptic drugs, tricyclic antidepressants, second-generation antidepressants, sedative/hypnotics and anxiolytics.

        Only 22.7% of patients felt that their prescribed medications were extremely or very effective, and only 22.4% were extremely or very satisfied with their medications.



        The study was sponsored by Pfizer Global Pharmaceuticals.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send